Colorectal cancer is the third most diagnosed cancer in Canada, with approximately 26,900 Canadians diagnosed in 2020. Epidermal Growth Factor Receptor inhibitor (EGFRi) therapy is an effective treatment option for metastatic colorectal cancer (mCRC), but is associated with dermatologic toxicity.
This video will provide education to clinicians on identifying and managing acneiform rash associated with EGFRi therapy in the treatment of mCRC. The goal is to engage clinicians in multidisciplinary collaboration for optimal patient care.
This program has received an educational grant or in-kind support from Amgen Canada.